Steve is co-founder, Chief Executive Officer and board member of MONOGENIC Pharmaceuticals, a spin-off from the Montreal Heart Institute. He is a passionate team worker entrepreneur and widely recognized scientist with over 15 years research experience in the competitive field of PCSK9, lipid metabolism and atherosclerotic cardiovascular diseases. With MONOGENIC, he successfully established 7 innovative drug development lipid-lowering pipelines and prioritized small molecule R&D programs from drug discovery towards in vivo POC. In addition to be a lead co-inventor of MONOGENIC’s patent portfolio, he is actively involved in the management and dynamic structuration of the business plan and rounds of financing.

Steve has completed MSc and PhD in Molecular Biology form the Université de Montréal after he joined the team of Dr. Nabil Seidah at the Clinical Research Institute of Montreal in 2003, the same year the laboratory published the identification of PCSK9 and its link to familial hypercholesterolemia with Dre Catherine Boileau’s team at Inserm. In 2011, he joined his great scientific partner Dr. Mayer (CSO) at the Montreal Heart Institute to co-found with Dr. Jean-Claude Tardif MONOGENIC in 2016. Over the years, he questioned, revisited published papers and co-led scientific discoveries notably the identification of PCSK9 natural inhibitors and, in close collaboration with the medicinal chemist Dr. Stranix, orally available small molecules both having high therapeutic potentials as emerging lipid-lowering therapies.

Since then, he is really encouraged and confident that MONOGENIC’s efforts will translate and fulfill the urgent clinical needs of affordable medications for patients with high cardiovascular risk and familial hypercholesterolemia.